MX2021004566A - Compuestos terapeuticos. - Google Patents
Compuestos terapeuticos.Info
- Publication number
- MX2021004566A MX2021004566A MX2021004566A MX2021004566A MX2021004566A MX 2021004566 A MX2021004566 A MX 2021004566A MX 2021004566 A MX2021004566 A MX 2021004566A MX 2021004566 A MX2021004566 A MX 2021004566A MX 2021004566 A MX2021004566 A MX 2021004566A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- therapeutic compounds
- relates
- present
- nrf2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos que son activadores de Nrf2. Los compuestos tienen la fórmula estructural I definida en la presente. La presente invención también se refiere a procesos para la preparación de estos compuestos, a composiciones farmacéuticas que los comprenden y a su uso en el tratamiento de enfermedades o trastornos asociados con la activación de Nrf2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1817193.4A GB201817193D0 (en) | 2018-10-22 | 2018-10-22 | Tetrahydroisoquinoline compounds |
GBGB1907674.4A GB201907674D0 (en) | 2019-05-30 | 2019-05-30 | Tetrahydroisoquinoline compounds |
PCT/GB2019/053012 WO2020084300A1 (en) | 2018-10-22 | 2019-10-22 | Therapeutic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021004566A true MX2021004566A (es) | 2021-06-08 |
Family
ID=68393021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021004566A MX2021004566A (es) | 2018-10-22 | 2019-10-22 | Compuestos terapeuticos. |
Country Status (23)
Country | Link |
---|---|
US (1) | US20220002286A1 (es) |
EP (2) | EP3870578B1 (es) |
JP (1) | JP2022514437A (es) |
KR (1) | KR20210080474A (es) |
CN (1) | CN112996785A (es) |
AU (1) | AU2019364717B2 (es) |
BR (1) | BR112021007513A2 (es) |
CA (1) | CA3114859A1 (es) |
DK (1) | DK3870578T3 (es) |
ES (1) | ES2963613T3 (es) |
FI (1) | FI3870578T3 (es) |
HR (1) | HRP20231306T1 (es) |
HU (1) | HUE064111T2 (es) |
IL (1) | IL282330A (es) |
LT (1) | LT3870578T (es) |
MX (1) | MX2021004566A (es) |
PH (1) | PH12021550872A1 (es) |
PL (1) | PL3870578T3 (es) |
PT (1) | PT3870578T (es) |
RS (1) | RS64836B1 (es) |
SG (1) | SG11202103253YA (es) |
SI (1) | SI3870578T1 (es) |
WO (1) | WO2020084300A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL280950B2 (en) | 2018-08-20 | 2023-12-01 | Janssen Pharmaceutica Nv | KEAP1-NRF2 protein-protein interaction inhibitors |
GB202005863D0 (en) * | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
GB202005852D0 (en) * | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
CN114507181B (zh) * | 2020-11-17 | 2024-03-26 | 中国医学科学院药物研究所 | 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用 |
WO2023073364A1 (en) | 2021-10-25 | 2023-05-04 | C4X Discovery Limited | Tetrahydroisoquinoline compounds that are keap1 binders |
IL312793A (en) * | 2022-01-07 | 2024-07-01 | Chugai Pharmaceutical Co Ltd | A nitrogen-containing heterocyclic compound with an NRF2 activating effect |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0330360B1 (en) * | 1988-02-19 | 1993-12-01 | SmithKline Beecham Farmaceutici S.p.A. | 1,2,3,4-Tetrahydroisoquinolines, processes for their preparation, and their use as kappa-receptor agonists |
ES2699226T3 (es) * | 2011-10-14 | 2019-02-08 | Bristol Myers Squibb Co | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa |
US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
CN103450079B (zh) * | 2013-08-14 | 2015-07-29 | 中国药科大学 | 四氢异喹啉羟基衍生物、其制备方法及其医药用途 |
AR110590A1 (es) * | 2016-12-27 | 2019-04-10 | Biogen Ma Inc | Activador de nrf2 |
GB202005863D0 (en) * | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
GB202005852D0 (en) * | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
-
2019
- 2019-10-22 EP EP19795615.4A patent/EP3870578B1/en active Active
- 2019-10-22 EP EP23191389.8A patent/EP4252755A3/en active Pending
- 2019-10-22 SI SI201930662T patent/SI3870578T1/sl unknown
- 2019-10-22 DK DK19795615.4T patent/DK3870578T3/da active
- 2019-10-22 MX MX2021004566A patent/MX2021004566A/es unknown
- 2019-10-22 SG SG11202103253YA patent/SG11202103253YA/en unknown
- 2019-10-22 PL PL19795615.4T patent/PL3870578T3/pl unknown
- 2019-10-22 PT PT197956154T patent/PT3870578T/pt unknown
- 2019-10-22 AU AU2019364717A patent/AU2019364717B2/en active Active
- 2019-10-22 FI FIEP19795615.4T patent/FI3870578T3/fi active
- 2019-10-22 BR BR112021007513-5A patent/BR112021007513A2/pt unknown
- 2019-10-22 KR KR1020217015269A patent/KR20210080474A/ko unknown
- 2019-10-22 HR HRP20231306TT patent/HRP20231306T1/hr unknown
- 2019-10-22 LT LTEPPCT/GB2019/053012T patent/LT3870578T/lt unknown
- 2019-10-22 HU HUE19795615A patent/HUE064111T2/hu unknown
- 2019-10-22 JP JP2021546488A patent/JP2022514437A/ja active Pending
- 2019-10-22 CN CN201980071533.XA patent/CN112996785A/zh active Pending
- 2019-10-22 RS RS20231069A patent/RS64836B1/sr unknown
- 2019-10-22 WO PCT/GB2019/053012 patent/WO2020084300A1/en active Application Filing
- 2019-10-22 CA CA3114859A patent/CA3114859A1/en active Pending
- 2019-10-22 ES ES19795615T patent/ES2963613T3/es active Active
- 2019-10-22 US US17/287,942 patent/US20220002286A1/en active Pending
-
2021
- 2021-04-14 IL IL282330A patent/IL282330A/en unknown
- 2021-04-19 PH PH12021550872A patent/PH12021550872A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUE064111T2 (hu) | 2024-02-28 |
CA3114859A1 (en) | 2020-04-30 |
EP3870578A1 (en) | 2021-09-01 |
PT3870578T (pt) | 2023-11-15 |
HRP20231306T1 (hr) | 2024-02-02 |
ES2963613T3 (es) | 2024-04-01 |
EP4252755A2 (en) | 2023-10-04 |
PL3870578T3 (pl) | 2024-03-04 |
EP3870578B1 (en) | 2023-08-16 |
JP2022514437A (ja) | 2022-02-10 |
LT3870578T (lt) | 2023-12-11 |
KR20210080474A (ko) | 2021-06-30 |
PH12021550872A1 (en) | 2021-12-06 |
IL282330A (en) | 2021-05-31 |
AU2019364717B2 (en) | 2023-07-20 |
FI3870578T3 (fi) | 2023-11-03 |
WO2020084300A1 (en) | 2020-04-30 |
EP4252755A3 (en) | 2023-11-08 |
DK3870578T3 (da) | 2023-11-13 |
BR112021007513A2 (pt) | 2021-07-27 |
SI3870578T1 (sl) | 2024-02-29 |
CN112996785A (zh) | 2021-06-18 |
AU2019364717A1 (en) | 2021-06-03 |
SG11202103253YA (en) | 2021-05-28 |
RS64836B1 (sr) | 2023-12-29 |
US20220002286A1 (en) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550872A1 (en) | Therapeutic compounds | |
MX2020001513A (es) | Agentes de union a clec9a y su uso. | |
PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2018006223A (es) | Moduladores de ror-gamma. | |
MX2018009257A (es) | Derivados de benzimidazol como moduladores de ror-gamma. | |
PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
MY201535A (en) | Therapeutic compounds | |
MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
MX2022013396A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. | |
MX2021002916A (es) | Pirfenidona enriquecida con deuterio y métodos para su uso. | |
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
MX2022014924A (es) | Moduladores de il-17a. | |
MX2022014925A (es) | Moduladores de il-17a. | |
MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
EP4364805A3 (en) | Novel pyridazines | |
MX2021004860A (es) | Piridazinas novedosas. | |
MX2017014752A (es) | Nuevos etinos de amidoheteroaril aroil hidrazida. | |
PH12018502280A1 (en) | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | |
MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. |